Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Liquid Biopsy Predicts Success of ICI Treatment in Lung Cancer Patients

By LabMedica International staff writers
Posted on 02 Jun 2022

Compared to an invasive tumor biopsy procedure, an extracellular vesicle-based liquid biopsy method was shown to better predict treatment response and survival in patients with non-small cell lung cancer who were undergoing treatment with immune-checkpoint inhibitors (ICIs).

Among the currently approved ICIs are those that target the PD-L1 molecule. PD-L1 binds to PD-1 on the surface of an immune cell, which inhibits immune cell activity. Thus, PD-L1 functions as a key regulator of T-cell activity. It appears that cancer-mediated upregulation of PD-L1 may inhibit T-cells that might otherwise attack tumor cells. Antibodies that bind to either PD-1 or PD-L1 and block their interaction may enable T-cells to attack the tumor.

Liquid biopsy is a method for the non-invasive and repeatable analysis of biological material in body fluids and is a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions.

Extracellular vesicles (EVs) are 40 to 200 micron cell-derived vesicles which play a critical role in cell-to-cell communication, and disease progression. These vesicles, which are present in all biological fluids, contain a wide variety of molecular species such as RNA, DNA, proteins, and lipids from their origin cells, offering a good source of biomarkers. The clinical relevance of EVs has remained largely undetermined, partially owing to challenges in EV analysis. Despite their huge clinical potential, the wide variety of methods for separating EVs from biofluids, which provide material of highly variable purity, and the lack of knowledge regarding methodological reproducibility have impeded the entry of EVs into the clinical arena.

In this regard, investigators at the The Mount Sinai Hospital / Mount Sinai School of Medicine (New York, NY, USA) evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs.

For this study, the investigators obtained blood samples from two cohorts of 33 and 24 patients with NSCLC receiving ICIs before and at the ninth week of treatment. In addition, a group of 15 patients receiving chemotherapy served as controls. EVs were isolated from the blood samples, and the protein expression of PD-L1 was measured in each group at both time points. Imaging scans of the patients’ tumors before and during treatment were evaluated with an innovative radiomics technology to create a model for prediction of immunotherapy response.

Radiomics is a method that extracts a large number of features from medical images using data-characterization algorithms. These features, termed radiomic features, have the potential to uncover patterns and characteristics present in a tumors that fail to be appreciated by the naked eye and which may be useful for predicting prognosis and therapeutic response for various cancer types.

Results obtained during the current study revealed a decrease in EVs PD-L1 in ICI responders in comparison to non-responders that was an independent biomarker for shorter progression-free survival and overall survival. In contrast, tissue PD-L1 expression, the most commonly used biomarker, was not predictive for either durable response or survival.

“These results will have an impact in the search for biomarkers to predict for immunotherapy outcome in patients with lung cancer as no truly reliable biomarkers have been found yet,” said senior author Dr. Christian Rolfo, professor of medicine at The Mount Sinai School of Medicine and president of the International Society of Liquid Biopsy. “If validated in larger prospective cohorts of patients, as we are working on now, this protein could complement or substitute for the tissue PD-L1 as the standard of care in these and other types of tumor patients receiving immunotherapy, especially because it is minimally invasive and can be repetitive during treatment, being able to detect changes in the tumor during the treatment in real time.”

The study was published in June 2, 2022, online edition of the Journal of Experimental & Clinical Cancer Research.


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.